Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronac Mamtani

Showing results (81-90 of 198) with videos related to

Pageof 20
Sort By:
Journal of Comparative Effectiveness Research|October 28, 2025
Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2Amanda M Kong, Dionna Andrean, Saarah Khan, et al.
Journal of the National Cancer Institute|August 11, 2012
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort studyRonac Mamtani, Kevin Haynes, Warren B Bilker, et al.
JAMA Network Open|February 20, 2020
Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung CancerSamuel U Takvorian, Arman Oganisian, Ronac Mamtani, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2014
The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov modelFrank I Scott, Ravy K Vajravelu, Meenakshi Bewtra, et al.
Gastroenterology|April 5, 2016
Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysisEdward Shelton, David Laharie, Frank I Scott, et al.
Clinical Genitourinary Cancer|August 23, 2020
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United StatesOliver Hale, Karl Patterson, Yizhen Lai, et al.
BJUI Compass|February 23, 2023
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot studyJeromy W Gotschall, C Kendall Major, Linda A Jacobs, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2019
Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With AgeRavy K Vajravelu, Lawrence Copelovitch, Mark T Osterman, et al.
Cancer|January 9, 2019
Association between age and sex and mortality after adjuvant therapy for renal cancerRonac Mamtani, Xin Victoria Wang, Bishal Gyawali, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's DiseaseFrank I Scott, Amneet K Hans, Mark E Gerich, et al.
Pageof 20

Showing results (81-90 of 198) with videos related to

Sort By:
Pageof 20
Journal of Comparative Effectiveness Research|October 28, 2025
Considerations for emulations of randomized controlled trials using real-world data: learnings from an emulation of MONALEESA-2Amanda M Kong, Dionna Andrean, Saarah Khan, et al.
Journal of the National Cancer Institute|August 11, 2012
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort studyRonac Mamtani, Kevin Haynes, Warren B Bilker, et al.
JAMA Network Open|February 20, 2020
Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung CancerSamuel U Takvorian, Arman Oganisian, Ronac Mamtani, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 14, 2014
The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov modelFrank I Scott, Ravy K Vajravelu, Meenakshi Bewtra, et al.
Gastroenterology|April 5, 2016
Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysisEdward Shelton, David Laharie, Frank I Scott, et al.
Clinical Genitourinary Cancer|August 23, 2020
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United StatesOliver Hale, Karl Patterson, Yizhen Lai, et al.
BJUI Compass|February 23, 2023
Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot studyJeromy W Gotschall, C Kendall Major, Linda A Jacobs, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2019
Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With AgeRavy K Vajravelu, Lawrence Copelovitch, Mark T Osterman, et al.
Cancer|January 9, 2019
Association between age and sex and mortality after adjuvant therapy for renal cancerRonac Mamtani, Xin Victoria Wang, Bishal Gyawali, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 18, 2020
Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's DiseaseFrank I Scott, Amneet K Hans, Mark E Gerich, et al.
Pageof 20